Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2013

Open Access 01-12-2013 | Research article

Muscle wasting associated with pathologic change is a risk factor for the exacerbation of joint swelling in collagen-induced arthritis in cynomolgus monkeys

Authors: Naoto Horai, Takaharu Nagaoka, Itsuro Higuchi, Hayato Kasai, Takako Yoshioka, Yoshihisa Umekita, Koichiro Fukuzaki, Ryoichi Nagata, Atsuro Miyata, Kazuhiro Abeyama

Published in: BMC Musculoskeletal Disorders | Issue 1/2013

Login to get access

Abstract

Background

Not only joint destruction but also muscle wasting due to rheumatoid cachexia has been problem in terms of quality of life of patients with rheumatoid arthritis (RA). In the present study, we performed histopathological examination and assessed relationships between characteristic parameters relating to muscle and joint swelling in a collagen-induced arthritis (CIA) model using cynomolgus monkeys (CMs).

Methods

Female CMs were used and CIA was induced by twice immunizations using bovine type II collagen with Freund’s complete adjuvant. Arthritis level was evaluated from the degree of swelling at the peripheral joints of the fore and hind limbs. Food consumption, body weight, and serum biochemical parameters were measured sequentially. Five or 6 animals per time point were sacrificed at 2, 3, 5 and 9 weeks after the first immunization to obtain quadriceps femoris specimens for histopathology. Pimonidazole hydrochloride was intravenously administered to determine tissue hypoxia in skeletal muscle.

Results

Gradual joint swelling was observed and the maximum arthritis score was noted at Week 5. In histopathology, necrosis of muscle fiber in the quadriceps femoris was observed only at Week 2 and the most significant findings such as degeneration, atrophy, and regeneration of muscle fiber were mainly observed at Week 5. Food consumption was decreased up to Week 4 but recovered thereafter. Body weight decreased up to Week 5 and did not completely recover thereafter. A biphasic increase in serum cortisol was also observed at Weeks 2 and 5. Histopathology showed that muscle lesions were mainly composed of degeneration and atrophy of the muscle fibers, and ATPase staining revealed that the changes were more pronounced in type II muscle fiber than type I muscle fiber. In the pimonidazole experiment, mosaic pattern in skeletal muscle was demonstrated in the intact animal, but not the CIA animal. Increased arthritis score was accompanied by a decrease in serum creatinine, a marker that reflects muscle mass.

Conclusions

Muscle wasting might exacerbate joint swelling in a collagen-induced arthritis model of cynomolgus monkeys.
Appendix
Available only for authorised users
Literature
1.
go back to reference Uchiyama Y, Yorozu K, Hashizume M, Moriya Y, Mihara M: Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol Pharm Bull. 2008, 31: 1159-1163. 10.1248/bpb.31.1159. [Pubmed]CrossRefPubMed Uchiyama Y, Yorozu K, Hashizume M, Moriya Y, Mihara M: Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol Pharm Bull. 2008, 31: 1159-1163. 10.1248/bpb.31.1159. [Pubmed]CrossRefPubMed
2.
go back to reference Kato A, Matsuo S, Takai H, Uchiyama Y, Mihara M, Suzuki : Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp Mol Pathol. 2008, 84: 262-270. 10.1016/j.yexmp.2008.03.003. [Pubmed]CrossRefPubMed Kato A, Matsuo S, Takai H, Uchiyama Y, Mihara M, Suzuki : Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp Mol Pathol. 2008, 84: 262-270. 10.1016/j.yexmp.2008.03.003. [Pubmed]CrossRefPubMed
3.
go back to reference Saito M, Yoshigae Y, Nakayama J, Ogawa Y, Ohtsuki M, Kurihara A, Ikeda T: Tissue distribution of humanized anti-human Fas monoclonal antibody (R-125224) based on fas antigen-antibody reaction in collagen-induced arthritis monkeys. Life Sci. 2007, 80: 2005-2014. 10.1016/j.lfs.2007.02.043. [Pubmed]CrossRefPubMed Saito M, Yoshigae Y, Nakayama J, Ogawa Y, Ohtsuki M, Kurihara A, Ikeda T: Tissue distribution of humanized anti-human Fas monoclonal antibody (R-125224) based on fas antigen-antibody reaction in collagen-induced arthritis monkeys. Life Sci. 2007, 80: 2005-2014. 10.1016/j.lfs.2007.02.043. [Pubmed]CrossRefPubMed
4.
go back to reference Sacre SM, Andreakos E, Taylor P, Feldmann M, Foxwell BM: Molecular therapeutic targets in rheumatoid arthritis. Expert Rev Mol Med. 2005, 7: 1-20. [Pubmed]CrossRefPubMed Sacre SM, Andreakos E, Taylor P, Feldmann M, Foxwell BM: Molecular therapeutic targets in rheumatoid arthritis. Expert Rev Mol Med. 2005, 7: 1-20. [Pubmed]CrossRefPubMed
5.
go back to reference Yang C, Robbins PD: Immunosuppressive exosomes: a new approach for treating arthritis. Int J Rheumatol. 2012, 2012: 8-573528. [Pubmed]CrossRef Yang C, Robbins PD: Immunosuppressive exosomes: a new approach for treating arthritis. Int J Rheumatol. 2012, 2012: 8-573528. [Pubmed]CrossRef
6.
go back to reference Ogasawara A, Utoh M, Nii K, Ueda A, Yoshikawa T, Kume T, Fukuzaki K: Effect of oral ketoconazole on oral and intravenous pharmacokinetics of simvastatin and its acid in cynomolgus monkeys. Drug Metab Dispos. 2009, 37: 122-128. 10.1124/dmd.108.022574. [Pubmed]CrossRefPubMed Ogasawara A, Utoh M, Nii K, Ueda A, Yoshikawa T, Kume T, Fukuzaki K: Effect of oral ketoconazole on oral and intravenous pharmacokinetics of simvastatin and its acid in cynomolgus monkeys. Drug Metab Dispos. 2009, 37: 122-128. 10.1124/dmd.108.022574. [Pubmed]CrossRefPubMed
7.
go back to reference Carr B, Norcross R, Fang Y, Lu P, Rodrigues AD, Shou M, Rushmore T, Booth-Genthe C: Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos. 2006, 34: 1703-1712. 10.1124/dmd.106.009977. [Pubmed]CrossRefPubMed Carr B, Norcross R, Fang Y, Lu P, Rodrigues AD, Shou M, Rushmore T, Booth-Genthe C: Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos. 2006, 34: 1703-1712. 10.1124/dmd.106.009977. [Pubmed]CrossRefPubMed
8.
go back to reference Prueksaritanont T, Kuo Y, Tang C, Li C, Qiu Y, Lu B, Strong-Basalyga K, Richards K, Carr B, Lin JH: In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab Dispos. 2006, 34: 1546-1555. 10.1124/dmd.106.009878. [Pubmed]CrossRefPubMed Prueksaritanont T, Kuo Y, Tang C, Li C, Qiu Y, Lu B, Strong-Basalyga K, Richards K, Carr B, Lin JH: In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab Dispos. 2006, 34: 1546-1555. 10.1124/dmd.106.009878. [Pubmed]CrossRefPubMed
9.
go back to reference Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, Clément-Lacroix P: Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol. 2007, 150: 862-872. 10.1038/sj.bjp.0707165. [Pubmed]CrossRefPubMedPubMedCentral Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, Clément-Lacroix P: Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol. 2007, 150: 862-872. 10.1038/sj.bjp.0707165. [Pubmed]CrossRefPubMedPubMedCentral
10.
go back to reference Fujii Y, Hirayama T, Ohtake H, Ono N, Inoue T, Sakurai T, Takayama T, Matsumoto K, Tsukahara N, Hidano S, Harima N, Nakazawa K, Igarashi Y, Goitsuka R: Amelioration of collagen-induced arthritis by a novel S1P1 antagonist with immunomodulatory activities. J Immunol. 2012, 188: 206-215. 10.4049/jimmunol.1101537. [Pubmed]CrossRefPubMed Fujii Y, Hirayama T, Ohtake H, Ono N, Inoue T, Sakurai T, Takayama T, Matsumoto K, Tsukahara N, Hidano S, Harima N, Nakazawa K, Igarashi Y, Goitsuka R: Amelioration of collagen-induced arthritis by a novel S1P1 antagonist with immunomodulatory activities. J Immunol. 2012, 188: 206-215. 10.4049/jimmunol.1101537. [Pubmed]CrossRefPubMed
11.
go back to reference Sato T, Fujii R, Konomi K, Yagishita N, Aratani S, Araya N, Aono H, Yudoh K, Suzuki N, Beppu M, Yamano Y, Nishioka K, Nakajima T: Overexpression of SPACIA1/SAAL1, a newly identified gene that is involved in synoviocyte proliferation, accelerates the progression of synovitis in mice and humans. Arthritis Rheum. 2011, 63: 3833-3842. 10.1002/art.30617. [Pubmed]CrossRefPubMed Sato T, Fujii R, Konomi K, Yagishita N, Aratani S, Araya N, Aono H, Yudoh K, Suzuki N, Beppu M, Yamano Y, Nishioka K, Nakajima T: Overexpression of SPACIA1/SAAL1, a newly identified gene that is involved in synoviocyte proliferation, accelerates the progression of synovitis in mice and humans. Arthritis Rheum. 2011, 63: 3833-3842. 10.1002/art.30617. [Pubmed]CrossRefPubMed
12.
go back to reference Zhang W, Wang B, Wang F, Zhang J, Yu J: CTLA4-FasL fusion product suppresses proliferation of fibroblast-like synoviocytes and progression of adjuvant-induced arthritis in rats. Mol Immunol. 2012, 50: 150-159. 10.1016/j.molimm.2012.01.007. [Pubmed]CrossRefPubMed Zhang W, Wang B, Wang F, Zhang J, Yu J: CTLA4-FasL fusion product suppresses proliferation of fibroblast-like synoviocytes and progression of adjuvant-induced arthritis in rats. Mol Immunol. 2012, 50: 150-159. 10.1016/j.molimm.2012.01.007. [Pubmed]CrossRefPubMed
13.
go back to reference Chou LW, Wang J, Chang PL, Hsieh YL: Hyaluronan modulates accumulation of hypoxia-inducible factor-1 alpha, inducible nitric oxide synthase, and matrix metalloproteinase-3 in the synovium of rat adjuvant-induced arthritis model. Arthritis Res Ther. 2011, 13: R90-10.1186/ar3365. [Pubmed]CrossRefPubMedPubMedCentral Chou LW, Wang J, Chang PL, Hsieh YL: Hyaluronan modulates accumulation of hypoxia-inducible factor-1 alpha, inducible nitric oxide synthase, and matrix metalloproteinase-3 in the synovium of rat adjuvant-induced arthritis model. Arthritis Res Ther. 2011, 13: R90-10.1186/ar3365. [Pubmed]CrossRefPubMedPubMedCentral
14.
go back to reference Schierbeck H, Lundbäck P, Palmblad K, Klevenvall L, Erlandsson-Harris H, Andersson U, Ottosson L: Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med. 2011, 17: 1039-1044. [Pubmed]CrossRefPubMedPubMedCentral Schierbeck H, Lundbäck P, Palmblad K, Klevenvall L, Erlandsson-Harris H, Andersson U, Ottosson L: Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med. 2011, 17: 1039-1044. [Pubmed]CrossRefPubMedPubMedCentral
15.
go back to reference Abreu JR, Krausz S, Dontje W, Grabiec AM, de Launay D, Nolte MA, Tak PP, Reedquist KA: Sustained T cell Rap1 signaling is protective in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Rheum. 2010, 62: 3289-3299. 10.1002/art.27656. [Pubmed]CrossRefPubMed Abreu JR, Krausz S, Dontje W, Grabiec AM, de Launay D, Nolte MA, Tak PP, Reedquist KA: Sustained T cell Rap1 signaling is protective in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Rheum. 2010, 62: 3289-3299. 10.1002/art.27656. [Pubmed]CrossRefPubMed
16.
go back to reference Wierda D, Smith HW, Zwickl CM: Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology. 2001, 158: 71-74. 10.1016/S0300-483X(00)00410-8. [Pubmed]CrossRefPubMed Wierda D, Smith HW, Zwickl CM: Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology. 2001, 158: 71-74. 10.1016/S0300-483X(00)00410-8. [Pubmed]CrossRefPubMed
17.
go back to reference Vierboom MP, Breedveld E, Kondova I, t Hart BA: Collagen-induced arthritis in common marmosets: a new nonhuman primate model for chronic arthritis. Arthritis Res Ther. 2010, 12: R200-10.1186/ar3172. [Pubmed]CrossRefPubMedPubMedCentral Vierboom MP, Breedveld E, Kondova I, t Hart BA: Collagen-induced arthritis in common marmosets: a new nonhuman primate model for chronic arthritis. Arthritis Res Ther. 2010, 12: R200-10.1186/ar3172. [Pubmed]CrossRefPubMedPubMedCentral
18.
go back to reference Chapman K, Pullen N, Graham M, Ragan I: Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov. 2007, 6: 120-126. 10.1038/nrd2242. [Pubmed]CrossRefPubMed Chapman K, Pullen N, Graham M, Ragan I: Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov. 2007, 6: 120-126. 10.1038/nrd2242. [Pubmed]CrossRefPubMed
19.
go back to reference Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE: Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012, 110: 420-424. 10.1016/j.amjcard.2012.03.044. [Pubmed]CrossRefPubMedPubMedCentral Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE: Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012, 110: 420-424. 10.1016/j.amjcard.2012.03.044. [Pubmed]CrossRefPubMedPubMedCentral
20.
go back to reference Bisoendial RJ, Stroes ES, Tak PP: Critical determinants of cardiovascular risk in rheumatoid arthritis. Curr Pharm Des. 2011, 17: 21-26. 10.2174/138161211795049741. [Pubmed]CrossRefPubMed Bisoendial RJ, Stroes ES, Tak PP: Critical determinants of cardiovascular risk in rheumatoid arthritis. Curr Pharm Des. 2011, 17: 21-26. 10.2174/138161211795049741. [Pubmed]CrossRefPubMed
21.
go back to reference Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, Dinarello CA, Rosenberg IH: Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest. 1994, 93: 2379-2386. 10.1172/JCI117244. [Pubmed]CrossRefPubMedPubMedCentral Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, Dinarello CA, Rosenberg IH: Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest. 1994, 93: 2379-2386. 10.1172/JCI117244. [Pubmed]CrossRefPubMedPubMedCentral
22.
go back to reference Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD: Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol. 2010, 6: 445-451. 10.1038/nrrheum.2010.105. [Pubmed]CrossRefPubMed Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD: Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol. 2010, 6: 445-451. 10.1038/nrrheum.2010.105. [Pubmed]CrossRefPubMed
23.
go back to reference Walsmith J, Roubenoff R: Cachexia in rheumatoid arthritis. Int J Cardiol. 2002, 85: 89-99. 10.1016/S0167-5273(02)00237-1. [Pubmed]CrossRefPubMed Walsmith J, Roubenoff R: Cachexia in rheumatoid arthritis. Int J Cardiol. 2002, 85: 89-99. 10.1016/S0167-5273(02)00237-1. [Pubmed]CrossRefPubMed
24.
go back to reference Plasqui G: The role of physical activity in rheumatoid arthritis. Physiol Behav. 2008, 94: 270-275. 10.1016/j.physbeh.2007.12.012. [Pubmed]CrossRefPubMed Plasqui G: The role of physical activity in rheumatoid arthritis. Physiol Behav. 2008, 94: 270-275. 10.1016/j.physbeh.2007.12.012. [Pubmed]CrossRefPubMed
25.
go back to reference Hollander AP, Corke KP, Freemont AJ, Lewis CE: Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum. 2001, 44: 1540-1544. 10.1002/1529-0131(200107)44:7<1540::AID-ART277>3.0.CO;2-7. [Pubmed]CrossRefPubMed Hollander AP, Corke KP, Freemont AJ, Lewis CE: Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum. 2001, 44: 1540-1544. 10.1002/1529-0131(200107)44:7<1540::AID-ART277>3.0.CO;2-7. [Pubmed]CrossRefPubMed
26.
go back to reference Peters CL, Morris CJ, Mapp PI, Blake DR, Lewis CE, Winrow VR: The transcription factors hypoxia-inducible factor 1alpha and Ets-1 co localize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum. 2004, 50: 291-296. 10.1002/art.11473. [Pubmed]CrossRefPubMed Peters CL, Morris CJ, Mapp PI, Blake DR, Lewis CE, Winrow VR: The transcription factors hypoxia-inducible factor 1alpha and Ets-1 co localize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum. 2004, 50: 291-296. 10.1002/art.11473. [Pubmed]CrossRefPubMed
27.
go back to reference Hamada T, Torikai M, Kuwazuru A, Tanaka M, Horai N, Fukuda T, Yamada S, Nagayama S, Hashiguchi K, Sunahara N, Fukuzaki K, Nagata R, Komiya S, Maruyama I, Fukuda T, Abeyama K: Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum. 2008, 58: 2675-2685. 10.1002/art.23729. [Pubmed]CrossRefPubMed Hamada T, Torikai M, Kuwazuru A, Tanaka M, Horai N, Fukuda T, Yamada S, Nagayama S, Hashiguchi K, Sunahara N, Fukuzaki K, Nagata R, Komiya S, Maruyama I, Fukuda T, Abeyama K: Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum. 2008, 58: 2675-2685. 10.1002/art.23729. [Pubmed]CrossRefPubMed
28.
go back to reference Hasselgren PO: Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care. 1999, 2: 201-205. 10.1097/00075197-199905000-00002. [Pubmed]CrossRefPubMed Hasselgren PO: Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care. 1999, 2: 201-205. 10.1097/00075197-199905000-00002. [Pubmed]CrossRefPubMed
29.
go back to reference Menconi M, Fareed M, O'Neal P, Poylin V, Wei W, Hasselgren PO: Role of glucocorticoids in the molecular regulation of muscle wasting. Crit Care Med. 2007, 35: S602-S608. 10.1097/01.CCM.0000279194.11328.77. [Pubmed]CrossRefPubMed Menconi M, Fareed M, O'Neal P, Poylin V, Wei W, Hasselgren PO: Role of glucocorticoids in the molecular regulation of muscle wasting. Crit Care Med. 2007, 35: S602-S608. 10.1097/01.CCM.0000279194.11328.77. [Pubmed]CrossRefPubMed
30.
go back to reference Schakman O, Gilson H, Thissen JP: Mechanisms of glucocorticoid-induced myopathy. J Endocrinol. 2008, 197: 1-10. 10.1677/JOE-07-0606. [Pubmed]CrossRefPubMed Schakman O, Gilson H, Thissen JP: Mechanisms of glucocorticoid-induced myopathy. J Endocrinol. 2008, 197: 1-10. 10.1677/JOE-07-0606. [Pubmed]CrossRefPubMed
31.
go back to reference Summers GD, Deighton CM, Rennie MJ, Booth AH: Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford). 2008, 47: 1124-1131. 10.1093/rheumatology/ken146. [Pubmed]CrossRef Summers GD, Deighton CM, Rennie MJ, Booth AH: Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford). 2008, 47: 1124-1131. 10.1093/rheumatology/ken146. [Pubmed]CrossRef
32.
go back to reference Rall LC, Walsmith JM, Snydman L, Reichlin S, Veldhuis JD, Kehayias JJ, Abad LW, Lundgren NT, Roubenoff R: Cachexia in rheumatoid arthritis is not explained by decreased growth hormone secretion. Arthritis Rheum. 2002, 46: 2574-2577. 10.1002/art.10714. [Pubmed]CrossRefPubMed Rall LC, Walsmith JM, Snydman L, Reichlin S, Veldhuis JD, Kehayias JJ, Abad LW, Lundgren NT, Roubenoff R: Cachexia in rheumatoid arthritis is not explained by decreased growth hormone secretion. Arthritis Rheum. 2002, 46: 2574-2577. 10.1002/art.10714. [Pubmed]CrossRefPubMed
33.
go back to reference Rall LC, Roubenoff R: Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford). 2004, 43: 1219-1223. 10.1093/rheumatology/keh321. [Pubmed]CrossRef Rall LC, Roubenoff R: Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford). 2004, 43: 1219-1223. 10.1093/rheumatology/keh321. [Pubmed]CrossRef
34.
go back to reference Magyar E, Talerman A, Mohacsy J, Wouters HW, de Bruijn WC: Muscle change in rheumatoid arthritis. A review of the literature with a study of 100 cases. Virchows Arch A Path Anat Histol. 1977, 373: 267-278. 10.1007/BF00432241. [Pubmed]CrossRef Magyar E, Talerman A, Mohacsy J, Wouters HW, de Bruijn WC: Muscle change in rheumatoid arthritis. A review of the literature with a study of 100 cases. Virchows Arch A Path Anat Histol. 1977, 373: 267-278. 10.1007/BF00432241. [Pubmed]CrossRef
35.
go back to reference Saini A, Al-Shanti N, Stewart CE: Waste management - cytokines, growth factors and cachexia. Cytokine Growth Factor Rev. 2006, 17: 475-486. 10.1016/j.cytogfr.2006.09.006. [Pubmed]CrossRefPubMed Saini A, Al-Shanti N, Stewart CE: Waste management - cytokines, growth factors and cachexia. Cytokine Growth Factor Rev. 2006, 17: 475-486. 10.1016/j.cytogfr.2006.09.006. [Pubmed]CrossRefPubMed
36.
go back to reference Penner G, Gang G, Sun X, Wray C, Hasselgren PO: C/EBP DNA-binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle. Am J Physiol Regul Integr Comp Physiol. 2002, 282: R439-R444. [Pubmed]CrossRefPubMed Penner G, Gang G, Sun X, Wray C, Hasselgren PO: C/EBP DNA-binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle. Am J Physiol Regul Integr Comp Physiol. 2002, 282: R439-R444. [Pubmed]CrossRefPubMed
37.
go back to reference Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T: Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008, 112: 3959-3964. 10.1182/blood-2008-05-155846. [Pubmed]CrossRefPubMed Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T: Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008, 112: 3959-3964. 10.1182/blood-2008-05-155846. [Pubmed]CrossRefPubMed
38.
go back to reference Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003, 107: 1303-1307. 10.1161/01.CIR.0000054612.26458.B2. [Pubmed]CrossRefPubMed Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003, 107: 1303-1307. 10.1161/01.CIR.0000054612.26458.B2. [Pubmed]CrossRefPubMed
39.
go back to reference Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D: Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008, 59: 1690-1697. 10.1002/art.24092. [Pubmed]CrossRefPubMed Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D: Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008, 59: 1690-1697. 10.1002/art.24092. [Pubmed]CrossRefPubMed
40.
go back to reference Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE: Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005, 52: 722-732. 10.1002/art.20878. [Pubmed]CrossRefPubMed Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE: Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005, 52: 722-732. 10.1002/art.20878. [Pubmed]CrossRefPubMed
41.
go back to reference Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation. 2002, 105: 1135-1143. 10.1161/hc0902.104353. [Pubmed]CrossRefPubMed Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation. 2002, 105: 1135-1143. 10.1161/hc0902.104353. [Pubmed]CrossRefPubMed
42.
go back to reference Hartog A, Hulsman J, Garssen J: Locomotion and muscle mass measures in a murine model of collagen-induced arthritis. BMC Musculoskelet Disord. 2009, 10: 59-10.1186/1471-2474-10-59. [Pubmed]CrossRefPubMedPubMedCentral Hartog A, Hulsman J, Garssen J: Locomotion and muscle mass measures in a murine model of collagen-induced arthritis. BMC Musculoskelet Disord. 2009, 10: 59-10.1186/1471-2474-10-59. [Pubmed]CrossRefPubMedPubMedCentral
Metadata
Title
Muscle wasting associated with pathologic change is a risk factor for the exacerbation of joint swelling in collagen-induced arthritis in cynomolgus monkeys
Authors
Naoto Horai
Takaharu Nagaoka
Itsuro Higuchi
Hayato Kasai
Takako Yoshioka
Yoshihisa Umekita
Koichiro Fukuzaki
Ryoichi Nagata
Atsuro Miyata
Kazuhiro Abeyama
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2013
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/1471-2474-14-205

Other articles of this Issue 1/2013

BMC Musculoskeletal Disorders 1/2013 Go to the issue